Quince Therapeutics filed Amendment No. 2 to update prior disclosure on its acquisition of Orphai Therapeutics. The amendment adds Orphai’s audited 2024–2025 financial statements, Q1 2026 interim results, unaudited pro forma combined financial information, and expanded business and risk-factor information for the combined company.
After the May 2026 acquisition, Quince is focused on serious pulmonary diseases led by inhaled rapamycin candidate LAM-001. In connection with the transaction, it received $115 million in upfront gross proceeds and may receive up to approximately $72 million more from certain warrants, plus up to $11 million from warrants issued to former Orphai stockholders. LAM-001 is in a 75-patient Phase 2b PH-ILD trial with data expected in Q1 2028, a fully enrolled Phase 2 BOS trial with top-line data expected in Q1 2027, and a planned Phase 2 SAPH study starting in late 2026 with data expected in Q4 2028.
LAM-001 has Orphan Drug Designation in the United States for BOS, sarcoidosis, pulmonary arterial hypertension and lymphangioleiomyomatosis, and in the European Union for BOS and lymphangioleiomyomatosis. Early Phase 1 and 2 studies showed clinically relevant improvements in pulmonary endpoints and low blood rapamycin concentrations around 1 ng/ml, and Quince intends to develop LAM-001 under the 505(b)(2) regulatory pathway while legacy A-T program eDSP has been discontinued after a Phase 3 trial missed its primary endpoints.
Quince Therapeutics, Inc. filed an amended report to correct its description of a previously approved reverse stock split. Stockholders had authorized a reverse split within a wide range, and the board set the final ratio at 1-for-20.
The Certificate of Amendment was filed on June 26, 2026 and the reverse split becomes effective at 11:59 p.m. Eastern Time on June 29, 2026, with split-adjusted trading on the Nasdaq Global Select Market starting June 30, 2026. Each 20 shares of common stock will be combined into 1 share, with fractional shares rounded up.
Immediately before the split there were 19,559,257 shares of common stock outstanding; immediately after effectiveness there will be approximately 977,963 shares outstanding. The split affects all holders uniformly and does not change percentage ownership, rights, or preferences. Options and warrants are proportionally adjusted, and the stock will trade under a new CUSIP while keeping the symbol QNCX.
Quince Therapeutics, Inc. approved and implemented a 1-for-20 reverse stock split of its common stock. The company filed a Certificate of Amendment in Delaware effective at 11:59 p.m. Eastern Time on June 29, 2026, and its shares will begin trading on a split-adjusted basis on June 30, 2026.
Every twenty shares of issued and outstanding common stock will be combined into one share, leaving stockholder ownership percentages generally unchanged, except that fractional shares will be settled in cash. Shares outstanding will decline from 19,559,257 immediately before the split to approximately 977,963 after the split. The stock will continue trading under the symbol QNCX with a new CUSIP number 22053A305.
Quince Therapeutics director David Lamond reported receiving a stock option grant covering 2,700 shares of common stock. The option has an exercise price of $0.947 per share and expires on June 11, 2036. All 2,700 shares underlying the option will vest in full on the one-year anniversary of the grant date. Following this award, Lamond holds options for 2,700 shares directly.
Quince Therapeutics director Christopher J. Senner received a grant of 2,700 stock options for common stock. These options have an exercise price of $0.947 per share and expire on June 11, 2036. All 2,700 options vest on the one-year anniversary of the grant date, and 2,700 derivative securities are reported as held directly after the transaction.
Quince Therapeutics, Inc. director and Chief Corp. Affairs Officer Brigette Roberts reported receiving multiple employee stock option awards for Quince common stock. On May 18, 2026, she was granted options covering several blocks of shares, including 6,837,319 options with an exercise price of $0.84 per share and additional grants such as 2,070,107 options at $0.09 per share, all classified as awards rather than market purchases or sales.
Footnotes explain these options were received in exchange for prior Orphai Therapeutics options under an Agreement and Plan of Merger involving Quince and Orphai entities. One option block begins vesting on May 21, 2026 in 36 equal monthly installments, conditioned on her continued service with the company. The filing shows only acquisitions of derivative awards, with no open-market stock trades.
Quince Therapeutics, Inc. filed an initial insider ownership report for Brigette Roberts, who is both a director and the company’s Chief Corporate Affairs Officer. The Form 3 data shows no reported purchases, sales, or other transactions in the company’s securities.
Quince Therapeutics, Inc. reported voting results from its annual stockholder meeting held online on June 11, 2026. Holders of 6,255,339 shares of common stock, representing approximately 38.37% of eligible shares, were present virtually or by proxy.
Stockholders elected Class I director June Bray to serve until the 2029 annual meeting, approved an amendment to the certificate of incorporation authorizing a reverse stock split in a range from 1-for-10 to 1-for-100 at the board’s discretion, and ratified BDO USA, P.C. as independent registered accounting firm for the fiscal year ending December 31, 2026.
Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers and approved the potential adjournment or postponement of the annual meeting to permit further proxy solicitation if necessary.
Quince Therapeutics, Inc. received a Schedule 13G disclosing that Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared beneficial ownership of common stock. The filing lists individual shared holdings around 1,403,580–1,403,697 shares, representing 7.2% of the class based on 19,559,257 shares outstanding.
The filing attributes the outstanding-share base to 16,300,740 shares outstanding as of May 4, 2026 plus 3,258,517 shares issued in connection with the Orphai Therapeutics acquisition.
Quince Therapeutics, Inc. has regained compliance with Nasdaq’s continued listing standards. Nasdaq staff reviewed the company’s Form 10-Q for the quarter ended March 31, 2026, which reported stockholders’ equity of $15,672,000, and determined that Quince now meets Nasdaq Listing Rule 5450(b)(1)(A).
This closes a prior deficiency notice issued on March 17, 2026, when Quince had failed to maintain a minimum market value of listed securities of $50,000,000 over 30 consecutive business days. Nasdaq has confirmed that the compliance matter is now closed and the company remains listed on the Nasdaq Global Select Market.